Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Since May 2022, mpox outbreaks have been occurring in non-mpox endemic areas, with the main population affected being men who have sex with men (MSM). Outbreak prevention and control depend not only on the effectiveness of vaccines but also on people’s willingness to receive these vaccines. Currently, there is lack of synthesis on the overall rates and influence factors of MSMs’ willingness to vaccinate against mpox. Therefore, we systematically reviewed studies that assessed the willingness of MSM to receive mpox vaccine. Methods Studies reporting mpox vaccination intentions among MSM were included by searching five databases (PubMed, Web of Science, EMBASE, CINAHL, and SCOPUS) from inception to May 12, 2024. The quality of the included literature was assessed using Joanna Briggs Institute’s critical appraisal tool. The data analysis software is Stata17. The systematic review has been registered with Prospero (registration ID: CRD42023452357). Results Twenty cross-sectional studies were included in the review. Meta-analysis results showed that the pooled willingness rate of vaccinate against mpox was 77.0% (95% CI: 73-81%, I2 = 99.4%). According to subgroup analysis, study countries (P = 0.002), research sample size (P = 0.001), and whether participants were infected with HIV (P = 0.002) may be sources of heterogeneity. The results of the meta-analysis of influencing factors showed that more number of sexual partners (OR: 2.24, 95%CI: 1.86–2.69), pre-exposure prophylaxis use (OR: 6.04, 95%CI: 4.80–7.61), history of sexually transmitted infections (OR: 2.96, 95%CI: 2.33–3.76), confidence in the vaccine’s effectiveness (OR: 2.79, 95%CI: 2.04–3.80) and safety (OR: 10.89, 95%CI: 5.22–22.72), fear of mpox infection (OR: 2.47, 95%CI: 2.11–2.89) and epidemics (OR: 2.87, 95%CI: 2.22–3.70), high mpox knowledge (OR: 2.35, 95%CI: 1.51–3.66), and the belief that people at high risk should be prioritized for vaccination (OR: 3.09, 95%CI: 1.40–6.84) were the facilitators of vaccine willingness. In addition, as a secondary outcome, meta-analysis results showed a pooled unwillingness rate of 16% (95% CI: 13-20%, I2 = 98.1%, 9 studies). Conclusion Willingness to vaccinate mpox was high among MSM, but some participants still had negative attitudes towards vaccination. Therefore, the Ministry of Public Health should develop targeted and effective strategies against those influencing factors to prevent and manage mpox outbreaks.
Background Since May 2022, mpox outbreaks have been occurring in non-mpox endemic areas, with the main population affected being men who have sex with men (MSM). Outbreak prevention and control depend not only on the effectiveness of vaccines but also on people’s willingness to receive these vaccines. Currently, there is lack of synthesis on the overall rates and influence factors of MSMs’ willingness to vaccinate against mpox. Therefore, we systematically reviewed studies that assessed the willingness of MSM to receive mpox vaccine. Methods Studies reporting mpox vaccination intentions among MSM were included by searching five databases (PubMed, Web of Science, EMBASE, CINAHL, and SCOPUS) from inception to May 12, 2024. The quality of the included literature was assessed using Joanna Briggs Institute’s critical appraisal tool. The data analysis software is Stata17. The systematic review has been registered with Prospero (registration ID: CRD42023452357). Results Twenty cross-sectional studies were included in the review. Meta-analysis results showed that the pooled willingness rate of vaccinate against mpox was 77.0% (95% CI: 73-81%, I2 = 99.4%). According to subgroup analysis, study countries (P = 0.002), research sample size (P = 0.001), and whether participants were infected with HIV (P = 0.002) may be sources of heterogeneity. The results of the meta-analysis of influencing factors showed that more number of sexual partners (OR: 2.24, 95%CI: 1.86–2.69), pre-exposure prophylaxis use (OR: 6.04, 95%CI: 4.80–7.61), history of sexually transmitted infections (OR: 2.96, 95%CI: 2.33–3.76), confidence in the vaccine’s effectiveness (OR: 2.79, 95%CI: 2.04–3.80) and safety (OR: 10.89, 95%CI: 5.22–22.72), fear of mpox infection (OR: 2.47, 95%CI: 2.11–2.89) and epidemics (OR: 2.87, 95%CI: 2.22–3.70), high mpox knowledge (OR: 2.35, 95%CI: 1.51–3.66), and the belief that people at high risk should be prioritized for vaccination (OR: 3.09, 95%CI: 1.40–6.84) were the facilitators of vaccine willingness. In addition, as a secondary outcome, meta-analysis results showed a pooled unwillingness rate of 16% (95% CI: 13-20%, I2 = 98.1%, 9 studies). Conclusion Willingness to vaccinate mpox was high among MSM, but some participants still had negative attitudes towards vaccination. Therefore, the Ministry of Public Health should develop targeted and effective strategies against those influencing factors to prevent and manage mpox outbreaks.
Background Monkeypox, now known as mpox, is a viral zoonotic disease caused by the monkeypox virus (MPXV) and is endemic to parts of Central and West Africa. Historically considered a regional health issue, mpox has gained global attention due to recent outbreaks in non-endemic regions. In 2022, the World Health Organization (WHO) declared mpox a Public Health Emergency of International Concern (PHEIC) following widespread transmission in countries where the virus had not been previously reported. This declaration was renewed in August 2024 after a surge in cases, particularly across Africa, including the Democratic Republic of Congo (DRC) and neighboring countries, where a more transmissible strain (Clade 1b) has rapidly spread, complicating efforts to control its transmission. Objective This study evaluated the socio-demographic factors that influenced monkeypox vaccination intentions among healthcare workers and the general population in Benue State, Nigeria. The findings provide insights into key determinants of vaccine hesitancy and acceptance, aimed at informing future public health interventions to improve vaccine uptake. Methodology This cross-sectional study, conducted from July to September 2024 in Makurdi, Benue State, Nigeria, evaluated socio-demographic factors influencing monkeypox vaccination intentions among healthcare workers (HCWs) and high-risk populations. The study, prompted by the WHO's declaration of monkeypox as a PHEIC, surveyed 377+ participants including HCWs, people living with HIV, and men who have sex with men. Results Key findings revealed significant differences in vaccination intentions based on marital status (p-value = 0.02), with no significant variations by gender or age. COVID-19 vaccination status was associated with monkeypox vaccination intentions. The 30-60 age group demonstrated the highest monkeypox awareness (75.2%). Healthcare workers showed high vaccination intent (83%) and were identified as the most reliable information source (p-value = 0.03). Higher education levels correlated with greater vaccine trust (p-value = 0.003), while lower education was linked to reduced awareness and increased stigma perceptions. Conclusion The study recommends enhancing HCW training, addressing socioeconomic barriers to vaccination, implementing targeted education campaigns, and focusing on trust-building strategies. Limitations include the study's urban focus and potential language barriers. In conclusion, socio-demographic factors significantly influence monkeypox vaccination intentions, underscoring the need for targeted interventions and improved vaccine access to mitigate the impact of monkeypox in Nigeria and affected regions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.